Related Experiment Video
Updated: Jul 1, 2026

Imaging In-Stent Restenosis: An Inexpensive, Reliable, and Rapid Preclinical Model
Published on: September 14, 2009
Stents in total occlusion for restenosis prevention. The multicentre randomized STOP study. The Israeli Working Group
C Lotan1, Y Rozenman, A Hendler
1Hadassah University Hospital, Jerusalem, Israel.
Coronary stenting significantly reduces restenosis and reocclusion after balloon angioplasty for chronic total occlusions. While effective, diffuse in-stent restenosis necessitates careful stent selection and placement.
Area of Science:
- Cardiology
- Interventional Cardiology
- Vascular Medicine
Background:
- Chronic total occlusions (CTO) of coronary arteries present a significant challenge.
- Percutaneous transluminal coronary angioplasty (PTCA) for CTO has a high restenosis rate.
- Coronary stenting is explored as a method to reduce restenosis and reocclusion post-PTCA.
Purpose of the Study:
- To evaluate if coronary stenting improves outcomes after successful balloon angioplasty for CTO.
- To compare restenosis and reocclusion rates between PTCA alone and PTCA with stenting in CTO.
Main Methods:
- A multicentre randomized study involving 96 patients with CTO.
- Patients with optimal PTCA results were randomized to either no further treatment or stent implantation (AVE microstent).
- Clinical follow-up at 1, 3, and 6 months, with coronary angiography at 6 months or earlier if indicated.
Main Results:
- Stent implantation was successful in all patients with no major complications.
- Binary restenosis rates were significantly lower in the stent group (42.1%) compared to the PTCA group (70.9%) (P=0.034).
- Reocclusion rates were 7.9% in the stent group versus 16.1% in the PTCA group. Restenosis patterns differed: focal in PTCA, diffuse in-stent in the stented group.
Conclusions:
- Coronary stenting significantly decreases restenosis and reocclusion rates in CTO.
- The diffuse nature of in-stent restenosis suggests careful consideration of stent length and placement at the occlusion site.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Coronary Artery Disease IV: Preventive Measures
Coronary Artery Disease V: Interprofessional Care
Acute Coronary Syndrome III: Diagnostic Studies
Atherosclerosis III: Management
Peripheral Artery Disease III: Interprofessional Care

